Treatment Pattern and Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients in Indonesia: Part of Asia-Pacific Breast Initiative II

Samuel Johny Haryono(1*), Noorwati Sutandyo(2), Ramadhan Karsono(3), Bambang Karsono(4), Denni Joko Purwanto(5), Alban Dien(6), Nugroho Prayogo(7), Walta Gautama(8)
(1) Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(2) Department of Hematology and Medical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(3) Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(4) Department of Hematology and Medical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(5) Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(6) Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(7) Department of Hematology and Medical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(8) Department of Surgical Oncology, Dharmais Hospital-National Cancer Center, Jakarta
(*) Corresponding Author
DOI : 10.33371/ijoc.v13i1.569

Abstract

Background: Breast cancer is the most diagnosed cancer among Indonesian women. Adjuvant chemotherapy plays a crucial role in the management of early breast cancer patients, with docetaxel-based regimens as a cornerstone therapy. The Asia-Pacific breast initiative II registry was established to evaluate safety parameters of docetaxel-based regimens in the Asia-Pacific region within 2009–2013 period. The result from Indonesia population is presented in this study.

Methods: This study was a part of International, longitudinal, multicenter, and observational research which included a group of consecutive early breast cancer patients with an intermediate-to-high risk of recurrence that was being treated with various docetaxel-based (anthracycline and non-anthracycline) adjuvant chemotherapy regimens during 2009–2013 in real-world clinical settings.


Results: The analysis included 49 subjects (2.8% of total study population). Majority of subjects received non-anthracycline-containing regimen (79.6%). Docetaxel was mainly prescribed in combination (63.27%). Chemotherapy-related adverse events were reported in all subjects. Mean number of cycles received by subjects was 5.5 cycles with dose intensity of 23.78 mg/m2/week.


Conclusions: The Indonesian result, as part of the Asia-Pacific Breast Initiative II Registry, identified some important factors that are relevant to clinical practice, including patient’s characteristics and treatment pattern of docetaxel use as adjuvant chemotherapy regimens.


 

Keywords


early breast cancer, docetaxel, adverse event, registry, Indonesi

Article Statistic

Abstract view : 351 times
PDF views : 233 times

Dimensions Metrics

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off

Full Text: PDF

How To Cite This :

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.